Logo image of KEQU

KEWAUNEE SCIENTIFIC CP (KEQU) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:KEQU - US4928541048 - Common Stock

37.51 USD
+0.01 (+0.03%)
Last: 1/12/2026, 8:03:22 PM
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to KEQU. KEQU was compared to 185 industry peers in the Health Care Equipment & Supplies industry. KEQU has only an average score on both its financial health and profitability. KEQU is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

KEQU had positive earnings in the past year.
KEQU had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: KEQU reported negative net income in multiple years.
In multiple years KEQU reported negative operating cash flow during the last 5 years.
KEQU Yearly Net Income VS EBIT VS OCF VS FCFKEQU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M -5M 10M 15M

1.2 Ratios

KEQU has a better Return On Assets (6.21%) than 84.86% of its industry peers.
KEQU has a better Return On Equity (16.81%) than 92.43% of its industry peers.
KEQU's Return On Invested Capital of 10.67% is amongst the best of the industry. KEQU outperforms 90.81% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for KEQU is in line with the industry average of 8.84%.
The 3 year average ROIC (9.90%) for KEQU is below the current ROIC(10.67%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 6.21%
ROE 16.81%
ROIC 10.67%
ROA(3y)6.79%
ROA(5y)2.22%
ROE(3y)17.94%
ROE(5y)5.55%
ROIC(3y)9.9%
ROIC(5y)N/A
KEQU Yearly ROA, ROE, ROICKEQU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 20 30

1.3 Margins

With a decent Profit Margin value of 4.11%, KEQU is doing good in the industry, outperforming 75.68% of the companies in the same industry.
Looking at the Operating Margin, with a value of 6.89%, KEQU is in the better half of the industry, outperforming 72.43% of the companies in the same industry.
With a Gross Margin value of 29.09%, KEQU is not doing good in the industry: 75.68% of the companies in the same industry are doing better.
KEQU's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 6.89%
PM (TTM) 4.11%
GM 29.09%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y25.96%
GM growth 5Y12.54%
KEQU Yearly Profit, Operating, Gross MarginsKEQU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20

5

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so KEQU is still creating some value.
The number of shares outstanding for KEQU remains at a similar level compared to 1 year ago.
Compared to 5 years ago, KEQU has more shares outstanding
Compared to 1 year ago, KEQU has a worse debt to assets ratio.
KEQU Yearly Shares OutstandingKEQU Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500K 1M 1.5M 2M 2.5M
KEQU Yearly Total Debt VS Total AssetsKEQU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

2.2 Solvency

KEQU has an Altman-Z score of 3.30. This indicates that KEQU is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 3.30, KEQU is doing good in the industry, outperforming 69.73% of the companies in the same industry.
The Debt to FCF ratio of KEQU is 12.32, which is on the high side as it means it would take KEQU, 12.32 years of fcf income to pay off all of its debts.
KEQU has a better Debt to FCF ratio (12.32) than 72.43% of its industry peers.
A Debt/Equity ratio of 0.85 indicates that KEQU is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.85, KEQU is doing worse than 73.51% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.85
Debt/FCF 12.32
Altman-Z 3.3
ROIC/WACC1.07
WACC9.95%
KEQU Yearly LT Debt VS Equity VS FCFKEQU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M 40M 60M

2.3 Liquidity

A Current Ratio of 2.48 indicates that KEQU has no problem at all paying its short term obligations.
KEQU has a Current ratio (2.48) which is in line with its industry peers.
KEQU has a Quick Ratio of 1.71. This is a normal value and indicates that KEQU is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.71, KEQU perfoms like the industry average, outperforming 46.49% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.48
Quick Ratio 1.71
KEQU Yearly Current Assets VS Current LiabilitesKEQU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

3

3. Growth

3.1 Past

KEQU shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -37.55%.
Looking at the last year, KEQU shows a very strong growth in Revenue. The Revenue has grown by 43.02%.
The Revenue has been growing by 10.27% on average over the past years. This is quite good.
EPS 1Y (TTM)-37.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-19.15%
Revenue 1Y (TTM)43.02%
Revenue growth 3Y12.5%
Revenue growth 5Y10.27%
Sales Q2Q%46.76%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KEQU Yearly Revenue VS EstimatesKEQU Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
KEQU Yearly EPS VS EstimatesKEQU Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 0.5 1 1.5

5

4. Valuation

4.1 Price/Earnings Ratio

KEQU is valuated cheaply with a Price/Earnings ratio of 7.43.
Based on the Price/Earnings ratio, KEQU is valued cheaply inside the industry as 97.84% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of KEQU to the average of the S&P500 Index (27.25), we can say KEQU is valued rather cheaply.
Industry RankSector Rank
PE 7.43
Fwd PE N/A
KEQU Price Earnings VS Forward Price EarningsKEQU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of KEQU indicates a rather cheap valuation: KEQU is cheaper than 97.30% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, KEQU is valued cheaply inside the industry as 90.27% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 21.02
EV/EBITDA 6.05
KEQU Per share dataKEQU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60 80

4.3 Compensation for Growth

The decent profitability rating of KEQU may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

KEQU does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

KEWAUNEE SCIENTIFIC CP

NASDAQ:KEQU (1/12/2026, 8:03:22 PM)

37.51

+0.01 (+0.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)12-10 2025-12-10/amc
Earnings (Next)03-10 2026-03-10
Inst Owners41.13%
Inst Owner Change0%
Ins Owners15.89%
Ins Owner Change-4.36%
Market Cap107.65M
Revenue(TTM)285.51M
Net Income(TTM)11.74M
Analysts82.86
Price TargetN/A
Short Float %1.66%
Short Ratio3.57
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 7.43
Fwd PE N/A
P/S 0.38
P/FCF 21.02
P/OCF 12.42
P/B 1.54
P/tB 2.67
EV/EBITDA 6.05
EPS(TTM)5.05
EY13.46%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)1.78
FCFY4.76%
OCF(TTM)3.02
OCFY8.05%
SpS99.48
BVpS24.34
TBVpS14.04
PEG (NY)N/A
PEG (5Y)N/A
Graham Number52.59
Profitability
Industry RankSector Rank
ROA 6.21%
ROE 16.81%
ROCE 13.73%
ROIC 10.67%
ROICexc 11.69%
ROICexgc 15.07%
OM 6.89%
PM (TTM) 4.11%
GM 29.09%
FCFM 1.79%
ROA(3y)6.79%
ROA(5y)2.22%
ROE(3y)17.94%
ROE(5y)5.55%
ROIC(3y)9.9%
ROIC(5y)N/A
ROICexc(3y)12.02%
ROICexc(5y)N/A
ROICexgc(3y)13.16%
ROICexgc(5y)N/A
ROCE(3y)12.97%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y25.96%
GM growth 5Y12.54%
F-Score4
Asset Turnover1.51
Health
Industry RankSector Rank
Debt/Equity 0.85
Debt/FCF 12.32
Debt/EBITDA 2.29
Cap/Depr 56.58%
Cap/Sales 1.24%
Interest Coverage 250
Cash Conversion 33.42%
Profit Quality 43.61%
Current Ratio 2.48
Quick Ratio 1.71
Altman-Z 3.3
F-Score4
WACC9.95%
ROIC/WACC1.07
Cap/Depr(3y)110.02%
Cap/Depr(5y)97.64%
Cap/Sales(3y)1.65%
Cap/Sales(5y)1.54%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-37.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-19.15%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)43.02%
Revenue growth 3Y12.5%
Revenue growth 5Y10.27%
Sales Q2Q%46.76%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y20.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y1290.93%
FCF growth 3YN/A
FCF growth 5Y49.49%
OCF growth 1Y51.55%
OCF growth 3YN/A
OCF growth 5Y28.86%

KEWAUNEE SCIENTIFIC CP / KEQU FAQ

What is the ChartMill fundamental rating of KEWAUNEE SCIENTIFIC CP (KEQU) stock?

ChartMill assigns a fundamental rating of 5 / 10 to KEQU.


What is the valuation status of KEWAUNEE SCIENTIFIC CP (KEQU) stock?

ChartMill assigns a valuation rating of 5 / 10 to KEWAUNEE SCIENTIFIC CP (KEQU). This can be considered as Fairly Valued.


How profitable is KEWAUNEE SCIENTIFIC CP (KEQU) stock?

KEWAUNEE SCIENTIFIC CP (KEQU) has a profitability rating of 6 / 10.


How financially healthy is KEWAUNEE SCIENTIFIC CP?

The financial health rating of KEWAUNEE SCIENTIFIC CP (KEQU) is 5 / 10.


Is the dividend of KEWAUNEE SCIENTIFIC CP sustainable?

The dividend rating of KEWAUNEE SCIENTIFIC CP (KEQU) is 0 / 10 and the dividend payout ratio is 0%.